Professional paper - Letter to the editor
Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism
British Journal of Clinical Pharmacology, 88 (2022), 10; 4654-4656. https://doi.org/10.1111/bcp.15451


Cite this document

Trkulja, V. (2022). Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism. British Journal of Clinical Pharmacology, 88. (10), 4654-4656. doi: 10.1111/bcp.15451

Trkulja, Vladimir. "Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism." British Journal of Clinical Pharmacology, vol. 88, no. 10, 2022, pp. 4654-4656. https://doi.org/10.1111/bcp.15451

Trkulja, Vladimir. "Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism." British Journal of Clinical Pharmacology 88, no. 10 (2022): 4654-4656. https://doi.org/10.1111/bcp.15451

Trkulja, V. (2022) 'Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism', British Journal of Clinical Pharmacology, 88(10), pp. 4654-4656. doi: 10.1111/bcp.15451

Trkulja V. Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism. British Journal of Clinical Pharmacology [Internet]. 2022 July 13 [cited 2024 December 02];88(10):4654-4656. doi: 10.1111/bcp.15451

V. Trkulja, "Fluvoxamine for COVID‐19 outpatients: For the time being, we might prefer to curb our optimism", British Journal of Clinical Pharmacology, vol. 88, no. 10, pp. 4654-4656, July 2022. [Online]. Available at: https://urn.nsk.hr/urn:nbn:hr:105:220170. [Accessed: 02 December 2024]

Please login to the repository to save this object to your list.